Molecular Zip Code based therapeutics to better treat Neurological Diseases
AivoCode is an emerging biotech startup pioneering the development of innovative and broad platform technologies to improve the treatment and management of neurological diseases by developing assets that promote neuroprotection and block neuroinflammation.
AivoCode’s unique technology is based on an unbiased screening approach to identify molecular “zip codes” specific to diseased regions or cell types in the brain.
Our Focus Areas
Neuroprotection is important because it directly addresses the processes that cause secondary brain injury after an initial insult like trauma, stroke, or lack of oxygen. While primary brain injury is the immediate, often irreversible damage caused by the initial event, secondary injury unfolds over hours to days and is largely preventable or reducible with timely neuroprotective measures
AivoCode’s lead candidate in neuroprotection aims to:
Limit or halt these secondary injury processes, thereby preserving more neural tissue and function.
Reduce inflammation and oxidative stress, which are major contributors to ongoing neuronal damage.
Promote neuronal survival and maintain cognitive and motor abilities, ultimately improving quality of life for those affected by brain injuries or neurological diseases.
Neuroprotection
Alzheimer’s disease (AD) is the most common progressive neurodegenerative disorder associated with aging. Limited success of recent clinical trials of various AD treatments may be attributable to treating the disease too late.
AivoCode is looking beyond amyloid in AD and other neurodegenerative conditions. AivoCode has identified an unexplored target that is present early in AD blood vessels and contributes to neuroinflammation and vascular dysfunction. AivoCode is now developing therapeutic antibodies to inhibit this target for an early therapeutic intervention.
Neurodegenerative Diseases
Ophthalmic indications
The eye can serve as the window into the brain. Despite its peripheral location, the retina or neural portion of the eye, is part of the central nervous system. The unique environment of the brain and retina is tightly regulated by blood–brain barrier and the blood-retinal barrier, respectively. Neuroinflammation and neurodegenerative process are critical in the pathology of many ophthalmic indications.
Optic neuropathies are disorders resulting from damage to the optic nerve due to a variety of causes, including vascular, inflammatory, genetic, toxic, compressive, infiltrative, or traumatic factors. They typically present with vision loss and color vision changes, and their management depends on identifying and treating the underlying cause to prevent permanent vision impairment.
Glaucoma is a multifactorial neurodegenerative disease that damages the eye's optic nerve and can result in vision loss and even blindness. Glaucoma is a leading cause of irreversible vision loss, affecting an estimated 80 million people worldwide and 3 million in the United States.
AivoCode is exploring AC01 application in different optic neuropathies including Glaucoma.
Our Team
Meet our team of world class Scientists & Thought Leaders
News
Learn more about our Discoveries & Awards
Get in Touch
We’d love to hear from you